Jinwon Life Sciences Publishes Study on Mechanism of Action of Self-Developed Intradermal Injector in International Journal

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 19th that the research results on the drug delivery mechanism of its self-developed suction-based intradermal injector GeneDerm have been published in the international academic journal Frontiers in Drug Delivery.

The study was conducted jointly with researchers from Rutgers University in New Jersey, USA. Drug delivery via intradermal injection (ID) is critically dependent on the size of the molecule, and the dispersion of the drug injected intradermally is inversely proportional to the molecular weight. In other words, larger molecules are concentrated within a small area at the injection site, whereas drugs with smaller molecular weights spread over a wider area.

Professor Hao Lin of the Department of Mechanical Engineering at Rutgers University, who participated in the study, stated, “Knowing the molecular weight of the administered drug alone allows for the calculation of tissue dispersion of the drug.” He emphasized, “GeneDerm, a suction-based intradermal injector, utilizes the fact that the suction effect is directly applied to DNA concentrated at the administration site, making it an ideal delivery system that enhances in vivo DNA delivery efficiency.”

Dr. Joel Maslow, Chief Medical Officer of GeneOne Life Science, said, “The clinical phase 1 results and preclinical study results of the COVID-19 DNA vaccine GLS-5310, which is the first clinical application case using GeneDerm, have demonstrated the excellent efficacy and safety of GeneDerm.” He added, “These research results are very important when applied to dermatological treatment fields, and can be applied in cases where multiple administrations are required for locally activated therapies such as monoclonal antibodies, or for treatments like melanoma, a type of skin cancer.”

Park Younggeun, CEO of GeneOne Life Science, said, “GeneDerm, our self-developed suction-based intradermal injector, is a next-generation DNA vaccine medical device that combines efficacy, administration convenience, safety, and cost competitiveness compared to the electroporation devices currently used for DNA vaccine administration.” He added, “By maximizing drug efficacy while dramatically improving administration convenience, we will actively expand the scalability of GeneDerm as an intradermal drug and vaccine delivery platform through optimization efforts, extending beyond the COVID-19 DNA vaccine to include indications such as skin cancer and expanding into the field of cell and gene therapy delivery.”